开发治疗性癌症疫苗：战场笔记
Creating therapeutic cancer vaccines: notes from the battlefield.
作者信息
Overwijk W W, Restifo N P
出版信息
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
Abstract
With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.
摘要
随着肿瘤抗原的鉴定以及如何针对这些抗原进行疫苗接种的知识的掌握，肿瘤免疫学领域面临着新的挑战。在本文中，作者认为未来成功的免疫疗法将激活抗肿瘤T细胞，而不会诱导其无反应性或凋亡死亡。
相似文献
1
Creating therapeutic cancer vaccines: notes from the battlefield.
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
2
Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
Tunis Med. 2005 Dec;83 Suppl 12:7-10.
3
Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?
Cancer Immunol Immunother. 1999 Oct;48(7):343-5. doi: 10.1007/s002620050584.
4
[Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].
Chirurg. 2002 Mar;73(3):255-61. doi: 10.1007/s00104-001-0407-z.
5
Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer.
Expert Opin Biol Ther. 2001 Mar;1(2):193-204. doi: 10.1517/14712598.1.2.193.
6
"Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany.
Cancer Immunol Immunother. 2011 Feb;60(2):299-303. doi: 10.1007/s00262-010-0912-3. Epub 2010 Aug 28.
7
Making and circumventing tolerance to cancer.
Eur J Immunol. 2009 Sep;39(9):2345-53. doi: 10.1002/eji.200939612.
8
Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Vaccine. 2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14.
9
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
Cancer Immunol Res. 2020 Dec;8(12):1465-1469. doi: 10.1158/2326-6066.CIR-20-0526.
10
[Immunotherapy of cancer].
Ugeskr Laeger. 2002 Jun 3;164(23):3008-16.
引用本文的文献
1
The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.
Brain Sci. 2024 Dec 21;14(12):1286. doi: 10.3390/brainsci14121286.
2
Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness.
Cancers (Basel). 2022 Aug 20;14(16):4032. doi: 10.3390/cancers14164032.
3
Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
Oncotarget. 2016 Dec 13;7(50):83601-83610. doi: 10.18632/oncotarget.13469.
4
Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.
PLoS One. 2013 Jun 18;8(6):e66659. doi: 10.1371/journal.pone.0066659. Print 2013.
5
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.
J Immunol. 2010 Jun 1;184(11):6514-21. doi: 10.4049/jimmunol.0900448. Epub 2010 May 7.
6
Adenosine receptors and cancer.
Handb Exp Pharmacol. 2009(193):399-441. doi: 10.1007/978-3-540-89615-9_14.
7
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
J Immunol. 2006 May 1;176(9):5213-22. doi: 10.4049/jimmunol.176.9.5213.
8
Immunotherapy for lymphomas.
Int J Hematol. 2003 Jun;77(5):444-55. doi: 10.1007/BF02986612.
9
Cancer vaccines: progress reveals new complexities.
J Clin Invest. 2002 Aug;110(3):289-94. doi: 10.1172/JCI16216.
本文引用的文献
1
Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses.
J Immunol. 2000 Sep 1;165(5):2404-9. doi: 10.4049/jimmunol.165.5.2404.
2
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
J Immunother. 2000 Jul-Aug;23(4):487-98. doi: 10.1097/00002371-200007000-00013.
3
Regulatory T cells: key controllers of immunologic self-tolerance.
Cell. 2000 May 26;101(5):455-8. doi: 10.1016/s0092-8674(00)80856-9.
4
Regulatory T cells in autoimmmunity*.
Annu Rev Immunol. 2000;18:423-49. doi: 10.1146/annurev.immunol.18.1.423.
5
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
Nat Med. 2000 May;6(5):493-5. doi: 10.1038/74955.
6
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Nat Med. 2000 Mar;6(3):332-6. doi: 10.1038/73193.
7
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
J Immunother. 2000 Jan;23(1):17-27. doi: 10.1097/00002371-200001000-00004.
8
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
J Immunol. 2000 Jan 15;164(2):562-5. doi: 10.4049/jimmunol.164.2.562.
9
TCR-Mediated internalization of peptide-MHC complexes acquired by T cells.
Science. 1999 Oct 29;286(5441):952-4. doi: 10.1126/science.286.5441.952.
10
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
J Immunol. 1999 Nov 1;163(9):4886-93.
Zotero 插件